A 58-year-old man from Delhi presents with progressive resting tremor, rigidity, and bradykinesia for 6 months. Clinical examination confirms pill-rolling tremor and cogwheel rigidity. Neuroimaging (CT brain) is normal. Which investigation is most appropriate to confirm the diagnosis and assess dopaminergic neuronal loss in the substantia nigra?

Explanation

## Investigation of Choice for Suspected Parkinson's Disease ### Clinical Context The patient presents with the cardinal triad of Parkinson's disease (PD): resting tremor, rigidity, and bradykinesia. While clinical diagnosis is usually sufficient, functional imaging that demonstrates dopaminergic deficit is the gold standard for confirming nigrostriatal degeneration. ### Why DAT SPECT is the Answer **Key Point:** DAT (dopamine transporter) SPECT imaging is the most widely available, cost-effective, and clinically validated functional neuroimaging modality for confirming dopaminergic neuronal loss in the substantia nigra and striatum in Parkinson's disease. **High-Yield:** DAT SPECT shows reduced tracer uptake in the putamen (typically asymmetric, often contralateral to the clinically more affected side) in PD. The pattern is highly specific for nigrostriatal degeneration and helps differentiate PD from essential tremor (normal DAT) and atypical parkinsonian syndromes (different uptake patterns). **Clinical Pearl:** In Indian practice, DAT SPECT is the most accessible functional imaging modality. It is: - Widely available in major centers - Cost-effective compared to PET - Highly sensitive (>90%) and specific (>95%) for detecting dopaminergic deficit - Useful for early diagnosis when clinical signs are subtle - Helps exclude secondary causes of parkinsonism ### Comparison of Functional Imaging Options | Investigation | Availability | Cost | Specificity for DA Loss | Clinical Use | |---|---|---|---|---| | DAT SPECT | High (India) | Low-moderate | Very high (>95%) | **Gold standard for PD diagnosis** | | 18F-fluorodopa PET | Low (few centers) | Very high | Very high | Research, atypical cases | | MRS | Moderate | Moderate | Low (metabolic changes, not specific) | Not diagnostic | | Transcranial sonography | Moderate | Low | Low (morphology, not function) | Screening tool only | ### Mechanism of DAT SPECT DAT SPECT uses a radiolabeled ligand (typically ¹²³I-FP-CIT or similar) that binds to dopamine transporters on presynaptic dopaminergic terminals. In PD, loss of dopaminergic neurons results in reduced tracer uptake in the striatum (putamen > caudate), creating a characteristic "comma-shaped" or asymmetric pattern. **Key Point:** The reduced striatal uptake reflects the underlying pathology — loss of dopaminergic neurons in the substantia nigra — and correlates with disease severity and motor symptom laterality. ### Why Other Options Are Suboptimal - **18F-fluorodopa PET:** More specific and sensitive but requires a PET cyclotron (rare in India), very expensive, and reserved for research or atypical diagnostic dilemmas. - **MRS:** Detects metabolic changes (lactate, GABA, glutamate) but is not specific for dopaminergic loss and does not directly visualize nigrostriatal degeneration. - **Transcranial sonography:** Can show hyperechogenicity of substantia nigra in PD but is operator-dependent, lacks specificity, and does not quantify dopaminergic function. ### Clinical Guideline The Movement Disorder Society recommends functional neuroimaging (DAT SPECT or PET) for diagnostic confirmation when clinical diagnosis is uncertain, to exclude mimics (essential tremor, drug-induced parkinsonism), or in early/atypical presentations [cite:Movement Disorder Society Guidelines].